详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

; Xiu, Peng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Shuni[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Yang, Xinfeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Fan, Jia[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ;

机构： [1]Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China [2]Second Ward Gastroenterol Dept, Shanxi, Peoples R China [3]Shanghai East Hosp, Dept Oncol, Shanghai, Peoples R China [4]USTC Anhui Prov Hosp, Affiliated Hosp 1, Oncol Chemotherapy Dept, Hefei, Peoples R China [5]Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China [6]Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China [7]Anyang Canc Hosp, Dept Med Oncol, Anyang, Peoples R China [8]Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China [9]Nanjing Med Univ, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Dept Med Oncol,Jiangsu Canc Hosp, Nanjing, Peoples R China [10]Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China [11]Guangdong Pharm, Affiliated Hosp 1, Sch Clin Med, Guangzhou, Peoples R China [12]Guangxi Med Univ, Affiliated Tumor Hosp, Dept Radio therapy, Nanning, Peoples R China [13]Yangzhou Univ, Dept Oncol, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China [14]Sichuan Canc Hosp Inst, Canc Hosp affiliate Sch Med, Dept Abdominal Med Oncol, Sichuan Canc Ctr, Chengdu, Peoples R China [15]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res Dev, Shanghai, Peoples R China [16]Fudan Univ Zhongshan Hosp, Shanghai, Peoples R China

出处：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China [2]Second Ward Gastroenterol Dept, Shanxi, Peoples R China [3]Shanghai East Hosp, Dept Oncol, Shanghai, Peoples R China [4]USTC Anhui Prov Hosp, Affiliated Hosp 1, Oncol Chemotherapy Dept, Hefei, Peoples R China [5]Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China [6]Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China [7]Anyang Canc Hosp, Dept Med Oncol, Anyang, Peoples R China [8]Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China [9]Nanjing Med Univ, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Dept Med Oncol,Jiangsu Canc Hosp, Nanjing, Peoples R China [10]Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China [11]Guangdong Pharm, Affiliated Hosp 1, Sch Clin Med, Guangzhou, Peoples R China [12]Guangxi Med Univ, Affiliated Tumor Hosp, Dept Radio therapy, Nanning, Peoples R China [13]Yangzhou Univ, Dept Oncol, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China [14]Sichuan Canc Hosp Inst, Canc Hosp affiliate Sch Med, Dept Abdominal Med Oncol, Sichuan Canc Ctr, Chengdu, Peoples R China [15]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res Dev, Shanghai, Peoples R China [16]Fudan Univ Zhongshan Hosp, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study

文献详情